Recently, immune-checkpoint inhibitor (ICI) targeting programmed death-1 (PD-1) and programmed death ligand-1 [PD-L1 (CD274)] have been investigated in ovarian cancer, but the clinical response of these inhibitors is quite limited (Disis et al., 2019; Matulonis et al., 2019). This evidence concerns the gene CD274 and ovarian cancer.